SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999; 49: 3364.
  • 2
    Sternberg C. The treatment of advanced bladder cancer. Ann Oncol. 1995; 6: 113126.
  • 3
    Sternberg C, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989; 12: 24482458.
  • 4
    Loehrer PJ, Einhorn LH, Elson P, et al. A randomized comparison of cisplatin alone or combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992; 10: 10661072.
  • 5
    Logothetis C, Dexeus F, Finn L, et al. A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990; 8: 10501055.
  • 6
    Saxaman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicine in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997; 15: 25642569.
  • 7
    Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer. Ann Oncol. 1994; 5: 182185.
  • 8
    Lorusso V, Pollera CF, Antimi M, et al. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum: Italian Cooperative Group on Bladder Cancer. Eur J Cancer. 1998; 34: 12081212.
  • 9
    Moore MJ, Tannock I, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997; 15: 34413445.
  • 10
    Stadler MA, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997; 15: 33943398.
  • 11
    Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of urothelium: a Phase II trial of the Eastern Cooperative Oncology Group (E1892). J Clin Oncol. 1994; 12: 22642270.
  • 12
    De Wit R, Kruit WHJ, Stoter G, de Boer M, Kerger J, Verweij J. Docetaxel (taxotere): an active agent in metastatic urothelial cancer; results of Phase II study in non-chemotherapy pretreated patients. Br J Cancer. 1998; 78: 13421345.
  • 13
    von der Maase H, Andersen L, Crinò L, Weinknecht S, Dogliotti L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a Phase II clinical trial. Ann Oncol. 1999; 10: 14611465.
  • 14
    Moore MJ, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a Phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999; 17: 28762881.
  • 15
    Kaufman D, Roghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000; 18: 19211927.
  • 16
    Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a Phase II trial of Minnie Pearl Cancer Research Network. J Clin Oncol. 2001; 19: 30183024.
  • 17
    Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001; 19: 25272533.
  • 18
    von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J Clin Oncol. 2000; 18: 30683077.
  • 19
    Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev. 1993; 19: 197.
  • 20
    Cacciari N, Martoni A, Pannuti F, et al. A new regimen of cisplatin, epirubicin and methotrexate (PEM-3) as a primary chemotherapy for locally advanced bladder cancer. Tumori. 1996; 82 (4): 364368.
  • 21
    Skarlos DV, Aravantinos G, Linardou E, et al. Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (carbo-MVE) in transitional cell urothelial cancer. Eur Urol. 1997; 31 (4): 420427.
  • 22
    Lorusso V, Pagliarulo A, Selvaggi FP, et al. Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin). J Chemother. 1996; 8 (2): 154158.
  • 23
    Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′-2 ′-difluoro-2′-deoxycytidine). Cancer Res. 1990; 50: 44174422.
  • 24
    Zoli W, Ricotti L, Barzanti F, et al. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer. 1999; 80: 413416.
  • 25
    Luftner D, Flath B, Akrivakis C, et al. Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a Phase I study. Invest New Drugs. 1998; 16: 141146.
  • 26
    Delacroix V, Dieras V, Vienz P, et al. Gemzar and epirubicin (EP) in patients with metastatic breast cancer (MBC): preliminary results of a Phase I study [abstract 520]. Proc Am Soc Clin Oncol. 1998; 17: 136a.
  • 27
    van Putten JW, Eppinga P, Erjavec Z, et al. Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter Phase I and II study. Br J Cancer. 2000; 82: 806811.
  • 28
    Pignata S, Varriale E, Casella G, et al. A Phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer. Ann Oncol. 2000; 11: 613616.
  • 29
    Neri B, Di Cello V, Biscione S, et al. Phase II evaluation of gemcitabine (GEM) and epirubicin (EPI) in advanced bladder cancer [abstract 1380]. Proc Am Soc Clin Oncol. 2000; 19: 351a.
  • 30
    Vaughn DJ, Malkowicz SB, Zoltick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol. 1998; 16: 255260.
  • 31
    Small EJ, Lew D, Redmann BG, et al. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol. 2000; 18: 25372544.
  • 32
    Shannon C, Crombie C, Brooks A, Lau H, Drummond M, Gurney H. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol. 2001; 12: 947952.